Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;37(2):125-130.
doi: 10.5455/msm.2025.37.125-130.

Reduction of Serum Interleukin-17 and Interleukin-23 Levels Following Narrow Band Ultraviolet B Treatment in Patients with Moderate-to-severe Psoriasis Vulgaris

Pham Thi Minh Phuong  1 , Tran Thi Huyen  1   2 , Quach Thi Ha Giang  1 , Trinh Minh Trang  1 , Hoang Thi Phuong  1 , Le Thi Hai Yen  1 , Nguyen Van Thuong  1   2 , Le Huu Doanh  1   2
Affiliations

Reduction of Serum Interleukin-17 and Interleukin-23 Levels Following Narrow Band Ultraviolet B Treatment in Patients with Moderate-to-severe Psoriasis Vulgaris

Pham Thi Minh Phuong et al. Mater Sociomed. 2025.

Abstract

Background: Psoriasis, a common skin disorder, involves immune cells and cytokines in its pathogenesis. Narrow band ultraviolet B (NB-UVB) treatment has demonstrated efficacy and safety in managing this condition.

Objective: This study aimed to assess changes in serum interleukin (IL)-17, IL-23, and tumor necrosis factor-alpha (TNF-α) levels during NB-UVB treatment for psoriasis vulgaris.

Methods: An interventional, pre-post comparative study was conducted on patients with moderate to severe psoriasis vulgaris undergoing NB-UVB treatment. Patients were randomly allocated to Group 1 (n=39) receiving NB-UVB based on minimal erythema dose (MED) and Group 2 (n=32) based on Fitzpatrick skin type classification. Serum IL-17, IL-23, and TNF-α levels were measured before treatment and upon achieving PASI75.

Results: There were no significant differences in serum IL-17, IL-23, and TNF-α levels between Group 1 and Group 2 at either time point. In Group 1, IL-17 levels decreased from median 2.6 pg/ml before treatment to 2.5 pg/ml at PASI75 (P=0.0107). In Group 2, IL-23 levels decreased from median 9.6 pg/ml pre-treatment to 1.3 pg/ml at PASI75 (P<0.0190). Across all patients, pre-treatment IL-17 and IL-23 levels (median 2.6 pg/ml and 7.1 pg/ml, respectively) were significantly higher compared to levels at PASI75 (P=0.0349 and P=0.0023, respectively).

Conclusion: NB-UVB effectively treats moderate to severe psoriasis vulgaris, leading to reduced serum IL-17 and IL-23 levels irrespective of MED-based or skin type-based dosing strategies.

Keywords: interleukin-17; interleukin-23; narrow band ultraviolet B; psoriasis; tumor necrosis factor-alpha.

PubMed Disclaimer

Conflict of interest statement

None to declare.

References

    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. The Lancet. 2021 Apr;397(10281):1301–1315. - PubMed
    1. Michalak-Stoma A, Bartosińska J, Raczkiewicz D, Kowal M, Kozak J, Gujski M, et al. Multiple Cytokine Analysis of Th1/Th2/Th9/Th17/Th22/Treg Cytokine Pathway for Individual Immune Profile Assessment in Patients with Psoriasis. Med Sci Monit Int Med J Exp Clin Res. 2022 Nov 24;28:e938277–e938277. - PMC - PubMed
    1. Lao J, Xie Z, Qin Q, Qin R, Li S, Yuan Y. Serum LL-37 and inflammatory cytokines levels in psoriasis. Immun Inflamm Dis. 2023 Mar;11(3):e802–e802. - PMC - PubMed
    1. Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol. 2012 Jul;67(1):139–147. - PubMed
    1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004 Jun 15;113(12):1664–1675. - PMC - PubMed

LinkOut - more resources